Natco Pharma Q1 PAT seen down by 24.1% at Rs 45.7 cr: Religare

Sales are expected to decrease by 20.6 percent Q-o-Q (up 44.4 percent Y-o-Y) to Rs 323.0 crore, according to Religare Research.

July 16, 2016 / 13:08 IST

live

bselive
nselive

Volume

Todays L/H

Religare Research has come out with its first quarter (April-June) earnings estimates for the India Pharmaceuticals sector. The brokerage house expects Natco Pharma to report a degrowth of 24.1 percent quarter-on-quarter (up of 61.9 percent year-on-year) in net profit at Rs 45.7 crore.Sales are expected to decrease by 20.6 percent Q-o-Q (up 44.4 percent Y-o-Y) to Rs 323.0 crore, according to Religare Research.Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 17.8 percent Q-o-Q (up 32.3 percent Y-o-Y) to Rs 76.0 crore.Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

first published: Jul 16, 2016 01:08 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347